These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 3479925)

  • 21. Differential susceptibility of young and old rat neuromuscular junctions to antibody-mediated AChR degradation in experimental autoimmune myasthenia gravis.
    Hoedemaekers A; Bessereau JL; Graus Y; Guyon T; Changeux JP; Berrih-Aknin S; Van Breda Vriesman P; De Baets M
    Ann N Y Acad Sci; 1998 May; 841():550-4. PubMed ID: 9668293
    [No Abstract]   [Full Text] [Related]  

  • 22. [Autoantibodies detected in acetylcholine receptor antibody-negative myasthenia gravis].
    Ohta R; Motomura M
    Rinsho Byori; 2014 Mar; 62(3):255-60. PubMed ID: 24800501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunopathology of myasthenia gravis.
    Drachman DB
    Fed Proc; 1979 Nov; 38(12):2613-5. PubMed ID: 227751
    [No Abstract]   [Full Text] [Related]  

  • 24. Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia.
    Gomez CM; Richman DP
    Proc Natl Acad Sci U S A; 1983 Jul; 80(13):4089-93. PubMed ID: 6575398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of acetylcholine receptor antibodies in myasthenia gravis.
    Appel SH; Elias SB; Chauvin P
    Fed Proc; 1979 Sep; 38(10):2381-5. PubMed ID: 478014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis.
    Xu K; Jha S; Hoch W; Dryer SE
    Neuroscience; 2006 Dec; 143(3):655-9. PubMed ID: 17081697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of disease-specific autoantibodies in seronegative myasthenia gravis.
    Bartoccioni E; Marino M; Evoli A; Ruegg MA; Scuderi F; Provenzano C
    Ann N Y Acad Sci; 2003 Sep; 998():356-8. PubMed ID: 14592896
    [No Abstract]   [Full Text] [Related]  

  • 28. Correction: direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients.
    PLOS ONE Staff
    PLoS One; 2015; 10(3):e0120947. PubMed ID: 25807480
    [No Abstract]   [Full Text] [Related]  

  • 29. Acquired canine myasthenia gravis: immunocytochemical localization of immune complexes at neuromuscular junctions.
    Pflugfelder CM; Cardinet GH; Lutz H; Holliday TA; Hansen RJ
    Muscle Nerve; 1981; 4(4):289-95. PubMed ID: 7019698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The auto-antigen repertoire in myasthenia gravis.
    Vrolix K; Fraussen J; Molenaar PC; Losen M; Somers V; Stinissen P; De Baets MH; Martínez-Martínez P
    Autoimmunity; 2010 Aug; 43(5-6):380-400. PubMed ID: 20380581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased uptake of acetylcholine-receptor antibody at motor endplate in myasthenic exacerbation.
    de Crousaz G; Fulpius BW
    Lancet; 1978 Jan; 1(8054):47. PubMed ID: 74528
    [No Abstract]   [Full Text] [Related]  

  • 32. [Antibodies to acetylcholine receptor. Diagnosis and therapeutic interest in myasthenia gravis (author's transl)].
    de Crousaz G
    Ann Chir; 1980 Mar; 34(3):188-92. PubMed ID: 7369693
    [No Abstract]   [Full Text] [Related]  

  • 33. [Acetylcholine receptors and myasthenia gravis].
    Yagi K; Uono M
    Nihon Rinsho; 1979; 37(8):3115-24. PubMed ID: 390183
    [No Abstract]   [Full Text] [Related]  

  • 34. Myasthenia gravis (first of two parts).
    Drachman DB
    N Engl J Med; 1978 Jan; 298(3):136-42. PubMed ID: 201840
    [No Abstract]   [Full Text] [Related]  

  • 35. Myasthenia gravis: State of the art and new therapeutic strategies.
    Souto EB; Lima B; Campos JR; Martins-Gomes C; Souto SB; Silva AM
    J Neuroimmunol; 2019 Dec; 337():577080. PubMed ID: 31670062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid degradation of "new" acetylcholine receptors at neuromuscular junctions.
    Stanley EF; Drachman DB
    Science; 1983 Oct; 222(4619):67-9. PubMed ID: 6623057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Familial autoimmune myasthenia gravis with different pathogenetic antibodies.
    Provenzano C; Arancio O; Evoli A; Rocca B; Bartoccioni E; de Grandis D; Tonali P
    J Neurol Neurosurg Psychiatry; 1988 Sep; 51(9):1228-30. PubMed ID: 3225607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of humoral immunity in myasthenia gravis.
    Zurn AD; Fulpius BW
    Prog Brain Res; 1979; 49():435-40. PubMed ID: 229518
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pseudo-internuclear ophthalmoplegia in myasthenia gravis].
    Bogdan I; Crisanda V
    Oftalmologia; 2011; 55(3):70-3. PubMed ID: 22428294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical features of myasthenia related with autoantibodies to muscle specific tyrosine kinase (MuSK)].
    Sanadze AG; Sidnev DV; Karganov MIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):72-6. PubMed ID: 21311492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.